Organon股价因未达到盈利预期并遭到分析师评级下调而下跌。 Organon stock fell after missing earnings expectations and receiving analyst downgrades.

公司股价跌至6.01美元, 分析师认为该公司的收益低于预期. Organon & Co. stock fell to $6.01 after missing earnings expectations, receiving a consensus "Reduce" rating from analysts. 公司将重点放在妇女健康方面, Wedmont私人资本在上个季度减少了76%的股份. Following a spin-off from Merck, the company focuses on women's health, and Wedmont Private Capital reduced its stake by 76% in the last quarter.